Clinical Trial Update: AT1001 for the Treatment of COVID-19 Related MIS-C [Phase 2]

View source ↗

Summary

A Phase 2 trial of AT1001 for COVID-19-related Multisystem Inflammatory Syndrome in Children has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multisystem Inflammatory Syndrome in Children

Drugs mentioned

• AT1001

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Covid19, Multisystem Inflammatory Syndrome in Children | Phase 2 | Status: TERMINATED